Viatris Company Profile
What is the competitive landscape for VIATRIS
VIATRIS has twenty-eight approved drugs.
There are five US patents protecting VIATRIS drugs.
Drugs and US Patents for Viatris
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-001 | Feb 22, 2005 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Viatris | NITROSTAT | nitroglycerin | TABLET;SUBLINGUAL | 021134-001 | May 1, 2000 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Viatris | NITROSTAT | nitroglycerin | TABLET;SUBLINGUAL | 021134-002 | May 1, 2000 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Viatris | EDLUAR | zolpidem tartrate | TABLET;SUBLINGUAL | 021997-001 | Mar 13, 2009 | AB | RX | Yes | No | 9,265,720 | ⤷ Start Trial | ⤷ Start Trial | |||
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-002 | Nov 2, 1990 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Viatris | EDLUAR | zolpidem tartrate | TABLET;SUBLINGUAL | 021997-002 | Mar 13, 2009 | AB | RX | Yes | Yes | 9,597,281 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Viatris
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viatris | GEODON | ziprasidone hydrochloride | CAPSULE;ORAL | 020825-002 | Feb 5, 2001 | 6,150,366 | ⤷ Start Trial |
| Viatris | MUSE | alprostadil | SUPPOSITORY;URETHRAL | 020700-001 | Nov 19, 1996 | 5,242,391 | ⤷ Start Trial |
| Viatris | EPIPEN JR. | epinephrine | INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | 019430-002 | Dec 22, 1987 | 8,048,035 | ⤷ Start Trial |
| Viatris | EPIPEN | epinephrine | INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | 019430-001 | Dec 22, 1987 | 7,449,012 | ⤷ Start Trial |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-001 | Nov 2, 1990 | 4,188,390 | ⤷ Start Trial |
| Viatris | EPIPEN | epinephrine | INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | 019430-001 | Dec 22, 1987 | 8,048,035 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VIATRIS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | CapsulesInhalation Solution | 0.02 mg/2 mL | ➤ Subscribe | 2009-01-21 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Injection (Auto-injector) | 0.15 mg/0.3 mL and 0.3 mg/0.3 mL | ➤ Subscribe | 2008-11-21 |
| ➤ Subscribe | Inhalation Solution | 300 mg/5 mL | ➤ Subscribe | 2009-06-29 |
| ➤ Subscribe | Tablets | 25 mg and 50 mg | ➤ Subscribe | 2004-11-19 |
| ➤ Subscribe | Sublingual Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-04-29 |
| ➤ Subscribe | Sublingual Tablets | 0.6 mg | ➤ Subscribe | 2011-12-29 |
| ➤ Subscribe | Tablets | 150 mg and 200 mg | ➤ Subscribe | 2005-11-09 |
| ➤ Subscribe | Injection (Auto-injector) | 0.15 mg/0.3 mL and 0.3 mg/0.3 mL | ➤ Subscribe | 2008-11-21 |
| ➤ Subscribe | Nasal Spray | 205.5 mcg/spray | ➤ Subscribe | 2011-12-15 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2004-10-25 |
| ➤ Subscribe | Sublingual Tablets | 0.3 mg, 0.4 mg and 0.6 mg | ➤ Subscribe | 2005-10-19 |
International Patents for Viatris Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1119580 | ⤷ Start Trial |
| Denmark | 2486942 | ⤷ Start Trial |
| Serbia | 58377 | ⤷ Start Trial |
| South Korea | 20140048349 | ⤷ Start Trial |
| South Korea | 20180030953 | ⤷ Start Trial |
| Japan | 2013047253 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Viatris Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435025 | 2019C/532 | Belgium | ⤷ Start Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| 1280520 | CA 2015 00017 | Denmark | ⤷ Start Trial | PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720 |
| 1214076 | SZ 49/2008 | Austria | ⤷ Start Trial | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON |
| 2435024 | 2190014-7 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210 |
| 2515855 | 201740046 | Slovenia | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR ITS SALT AND BECLOMETASONE DIPROPIONATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1208/001-005; DATE OF NATIONAL AUTHORISATION: 20170717; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 0771217 | CA 2006 00038 | Denmark | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

